Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Persistency of omalizumab response in severe persistent allergic asthma
2005-001099-11Phase 4Completed
- Sponsor
- Novartis
- Start
- Sep 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of omalizumab in allergic asthma, sponsored by Novartis. Started Sep 2005; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on 2005-001099-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001099-11.